1-4 of 4
Carole Beaulieu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3612: Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, in combination with an EGFR inhibitor

Marielle Fournel, Isabelle Dupont, Claire Bonfils, Marja Dubay, Hélène Ste-Croix, Carole Beaulieu, Normand Beaulieu, Christian Lemoyne, James Wang, Lubo Isakovic, Stephen Claridge, Oscar Saavedra, Franck Raeppel, Stephane Raeppel, Michael Mannion, Arkadii Vaisburg, Robert E. Martell, Jeffrey M. Besterman, Christiane R. Maroun
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 3612.
https://doi.org/10.1158/1538-7445.AM10-3612
Published: 15 April 2010
View article titled, Abstract 3612: Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, in combination with an EGFR inhibitor
Journal Articles

Preclinical development of MGCD265, a potent orally active c-Met/VEGFR multi-target kinase inhibitor

Normand Beaulieu, Carole Beaulieu, Isabelle Dupont, Hannah Nguyen, Ian Chute, Serge Gravel, Julien Durand, Marie-France Robert, Sylvain Lefebvre, Aihua Lu, Marja Dubay, Jubrail Rahil, Lubo Isakovic, Stephen Claridge, Oscar Saavedra, Stephane Raeppel, Michael Mannion, Naomy Bernstein, Lijie Zhan, Frederick Gaudette, Nancy Zhou, Franck Raeppel, Marie-Claude Granger, Robert Deziel, Arkadii Vaisburg, James Wang, Jeffrey Besterman, A.Robert Macleod, Christiane Maroun
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 4838.
Published: 01 May 2008
View article titled, Preclinical development of MGCD265, a potent orally active c-Met/VEGFR multi-target kinase inhibitor
Journal Articles

Evaluation of antitumor activity, anti-angiogenic activity and pharmacodynamic end points for orally active multi-targeted anti-angiogenic kinase inhibitors targeting c-MET, ron, VEGF and Tie-2 receptors

Hannah Nguyen, Normand Beaulieu, Annie Barsalou, Carole Beaulieu, Ian Chute, Isabelle Dupont, Julien Durand, Serge Gravel, Rowena Law, Marie-France Robert, Sylvain Lefebvre, Stephen Claridge, Franck Raeppel, Oscar Saavedra, Naomy Bernstein, Marie-Claude Granger, Lijie Zhan, David Llewellyn, Amal Wahhab, Robert Deziel, James Wang, Jeffrey M. Besterman, Arkadii Vaisburg, A. Robert Macleod
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 58.
Published: 15 April 2006
View article titled, Evaluation of antitumor activity, anti-angiogenic activity and pharmacodynamic end points for orally active multi-targeted anti-angiogenic kinase inhibitors targeting c-MET, ron, VEGF and Tie-2 receptors
Journal Articles

Sulfonamide Anilides, a Novel Class of Histone Deacetylase Inhibitors, Are Antiproliferative against Human Tumors

Marielle Fournel, Marie-Claude Trachy-Bourget, P. Theresa Yan, Ann Kalita, Claire Bonfils, Carole Beaulieu, Sylvie Frechette, Silvana Leit, Elie Abou-Khalil, Soon-Hyung Woo, Daniel Delorme, A. Robert MacLeod, Jeffrey M. Besterman, Zuomei Li
Journal: Cancer Research
Cancer Res (2002) 62 (15): 4325–4330.
Published: 01 August 2002
View article titled, Sulfonamide Anilides, a Novel Class of Histone Deacetylase Inhibitors, Are Antiproliferative against Human Tumors
Open the PDF for Sulfonamide Anilides, a Novel Class of Histone Deacetylase Inhibitors, Are Antiproliferative against Human Tumors in another window